公开(公告)号：US20190218289A1

公开(公告)日：2019-07-18

申请号：US16375238

申请日：2019-04-04

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： Stephen Willingham ,  Maureen Howard ,  Jie Liu ,  Ravindra Majeti ,  Susan Sweeney Prohaska ,  Anne Kathrin Volkmer ,  Jens-Peter Volkmer ,  Irving L. Weissman

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K38/18 ,  A61K38/17

CPC分类号： C07K16/2803 ,  A61K38/1774 ,  A61K38/1816 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  Y02A50/403 ,  Y02A50/41 ,  Y02A50/412 ,  A61K2300/00

摘要： Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.

公开(公告)号：US10350284B1

公开(公告)日：2019-07-16

申请号：US16371020

申请日：2019-03-31

申请人： Lior Carmon ,  VAXIL BIOTHERAPEUTICS LTD.

发明人： Lior Carmon

IPC分类号： A61K39/00 ,  A61K39/02 ,  A61K39/385 ,  A61K39/39 ,  A61K39/395 ,  A61K39/04

CPC分类号： A61K39/04 ,  A61K2039/6031 ,  A61K2039/6068 ,  A61K2039/6075 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/414

摘要： The invention provides peptide vaccines comprising the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. The invention provides in particular anti tuberculosis vaccines. The invention further provides compositions comprising the vaccines as well as their use to treat or prevent infection.

公开(公告)号：US20180312555A1

公开(公告)日：2018-11-01

申请号：US15895907

申请日：2018-02-13

申请人： Consejo Superior de Investigaciones Científicas (CSIC)

发明人： Maria del Carmen THOMAS CARAZO ,  Manuel Carlos LÓPEZ LÓPEZ ,  Darién LEDESMA ARROYO

IPC分类号： C07K14/44 ,  A61K39/008 ,  C12Q1/04 ,  C12Q1/6893 ,  A61K39/00

CPC分类号： C07K14/44 ,  A61K39/008 ,  A61K2039/53 ,  A61K2039/6043 ,  C12Q1/04 ,  C12Q1/6893 ,  Y02A50/41

摘要： The present invention claims an isolated nucleotide sequence characterized by encoding the PFR1 protein of Leishmania infantum or a fragment thereof. This PFR1 protein or a fragment thereof comprises at least a selected immunodominant epitope between the following group: SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4, SEQ ID No: 5, SEQ ID No: 6, SEQ ID No: 7 and SEQ ID No: 8, where the immunodominant epitope is able to induce an antigen-specific T cell cytotoxic immune response in an animal, against the kinetoplastids causing the leishmaniasis disease. The immunodominant epitopes are cytotoxic T-lymphocyte activators and they present a high binding affinity for A2 type MHC Class I molecule.

公开(公告)号：US20180282414A1

公开(公告)日：2018-10-04

申请号：US16006493

申请日：2018-06-12

申请人： Bristol-Myers Squibb Company

发明人： John P. COGSWELL ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

IPC分类号： C07K16/28 ,  G01N33/574 ,  C07K16/18 ,  A61K39/395

CPC分类号： C07K16/2818 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/76 ,  G01N33/57492 ,  G01N2333/70596 ,  G01N2800/52 ,  Y02A50/41 ,  Y02A50/412

摘要： The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

公开(公告)号：US20180273631A1

公开(公告)日：2018-09-27

申请号：US15934334

申请日：2018-03-23

申请人： UNIVERSITY OF SOUTHAMPTON

发明人： Martin John GLENNIE ,  Alison Louise TUTT ,  Aymen AL-SHAMKHANI

IPC分类号： C07K16/28 ,  A61K45/06 ,  A61K39/395 ,  A61K39/00

CPC分类号： C07K16/2878 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2875 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/74 ,  C07K2317/75 ,  Y02A50/403 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/466

摘要： Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.

公开(公告)号：US20180273624A1

公开(公告)日：2018-09-27

申请号：US16006365

申请日：2018-06-12

申请人： Bristol-Myers Squibb Company

发明人： John P. COGSWELL ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

IPC分类号： C07K16/28 ,  G01N33/574 ,  C07K16/18 ,  A61K39/395

CPC分类号： C07K16/2818 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/76 ,  G01N33/57492 ,  G01N2333/70596 ,  G01N2800/52 ,  Y02A50/41 ,  Y02A50/412

摘要： The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

公开(公告)号：US20180215823A1

公开(公告)日：2018-08-02

申请号：US15934447

申请日：2018-03-23

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Eric Smith ,  Nicholas J. Papadopoulos

IPC分类号： C07K16/28 ,  A61K39/00

CPC分类号： C07K16/2809 ,  A61K2039/505 ,  C07K16/2887 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/35 ,  C07K2317/734 ,  C07K2317/74 ,  C07K2317/92 ,  Y02A50/386 ,  Y02A50/403 ,  Y02A50/407 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/466 ,  Y02A50/487 ,  Y02A50/489

摘要： The present invention provides antibodies that bind to CD3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with high affinity and induce human T cell proliferation. The invention includes antibodies that bind CD3 and induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human CD20. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell tumors expressing CD20. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.

公开(公告)号：US10005804B2

公开(公告)日：2018-06-26

申请号：US15709688

申请日：2017-09-20

申请人： THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY

发明人： Michel L. Tremblay ,  Claudia Penafuerte ,  Matthew Feldhammer ,  George Zogopoulos ,  Cameron Black ,  Brian Kennedy

IPC分类号： C07F9/6553 ,  A61K31/67 ,  A61K35/15 ,  A61K31/662 ,  A61K39/39 ,  A61K45/06 ,  A61K39/00 ,  C12N9/16

CPC分类号： C07F9/655354 ,  A61K31/662 ,  A61K31/67 ,  A61K35/15 ,  A61K39/0011 ,  A61K39/39 ,  A61K45/06 ,  A61K2039/5154 ,  C12N9/16 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/414 ,  Y02A50/423 ,  Y02A50/478 ,  Y02A50/48 ,  Y02A50/491 ,  A61K2300/00

摘要： The invention encompasses the novel class of compounds represented by the Formula (I) below, which are inhibitors of the TC-PTP enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown above and methods of treating or preventing TC-PTP mediated diseases, including cancer, via their use in the activation of antigen-presenting cells, like dendritic cells, for applications in the immunotherapeutic treatment of diseases.

公开(公告)号：US20180170975A1

公开(公告)日：2018-06-21

申请号：US15815512

申请日：2017-11-16

申请人： Infectious Disease Research Institute

发明人： Steven G. REED ,  Rhea N. COLER ,  Gregory C. IRETON ,  Sylvie BERTHOLET

IPC分类号： C07K14/35 ,  G01N33/68 ,  A61K39/04 ,  C07K14/285

CPC分类号： C07K14/35 ,  A61K39/04 ,  A61K2039/55561 ,  C07K14/285 ,  C07K2319/00 ,  G01N33/5695 ,  G01N33/68 ,  G01N2469/20 ,  Y02A50/41 ,  Y02A50/55

摘要： The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.

公开(公告)号：US09993548B2

公开(公告)日：2018-06-12

申请号：US14161660

申请日：2014-01-22

申请人： Selecta Biosciences, Inc.

发明人： Roberto A. Maldonado

IPC分类号： A61K47/48 ,  A61K39/00 ,  C07K16/18 ,  A61K9/51 ,  A61K9/58 ,  A61K47/00 ,  A61K9/14 ,  A61K39/385 ,  A61K39/35 ,  G01N33/50 ,  G01N33/569 ,  B82Y5/00 ,  A61K39/36 ,  A61K9/127 ,  A61K38/38 ,  A61K31/192 ,  A61K38/13 ,  A61K38/18 ,  A61K47/50 ,  A61K47/52 ,  A61K47/54 ,  A61K47/59 ,  A61K47/64 ,  A61K47/69 ,  B82Y40/00

CPC分类号： A61K39/385 ,  A61K9/127 ,  A61K9/14 ,  A61K9/51 ,  A61K9/5115 ,  A61K9/5146 ,  A61K9/5153 ,  A61K31/192 ,  A61K38/13 ,  A61K38/1816 ,  A61K38/38 ,  A61K39/00 ,  A61K39/0008 ,  A61K39/001 ,  A61K39/35 ,  A61K39/36 ,  A61K47/50 ,  A61K47/52 ,  A61K47/544 ,  A61K47/593 ,  A61K47/643 ,  A61K47/69 ,  A61K47/6923 ,  A61K47/6929 ,  A61K47/6937 ,  A61K2039/5154 ,  A61K2039/55511 ,  A61K2039/55555 ,  A61K2039/577 ,  B82Y5/00 ,  B82Y40/00 ,  G01N33/505 ,  G01N33/56972 ,  G01N2333/7051 ,  G01N2333/70514 ,  G01N2333/70517 ,  Y02A50/401 ,  Y02A50/41 ,  A61K2300/00

摘要： Disclosed are synthetic nanocarrier methods, and related compositions, comprising B cell and/or MHC Class II-restricted epitopes and immunosuppressants in order to generate tolerogenic immune responses, such as the generation of antigen-specific regulatory B cells.